Northwest Biotherapeutics Inc (NWBO): Long-Term Debt
$60.04M
As of 2025-12-31
$51.97M
As of 2026-06-30
+40.8%
3-year compound annual growth
+32.4%
5-year compound annual growth
+10.2%
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $60.04M | -4.2% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $62.68M | +53.6% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $40.79M | +89.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $21.53M | -33.5% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $32.40M | +119.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $14.77M | +16.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $12.72M | -24.3% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $16.80M | -46.6% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $31.43M | -0.9% | 2019-04-02, Balance as of period end |
| 2016-12-31 | $31.71M | +39.0% | 2018-04-17, Balance as of period end |
| 2015-12-31 | $22.81M | n/a | 2017-04-17, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $60.04M | -4.2% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2024-12-31 | $25.00M | -16.7% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2025-03-31 | $807.2K | +27.8% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $150.0K | 0.0% |
| Bio Essence Corp (BIOE) | 2025-12-31 | $57.5K | +1.8% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $109.59M | +6.9% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $0 | n/a |
| Scienture Holdings, Inc. (SCNX) | 2024-12-31 | $2.90M | n/a |
| BioAge Labs, Inc. (BIOA) | 2024-12-31 | $8.50M | n/a |
Compare NWBO, RANI, SXTC, SXTP side by side · Screen every company in Pharmaceutical Preparations ↗